Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVX-060 + Sunitinib in Advanced Renal Cell Carcinoma
NCT00982657Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Sep 2009
- Primary completion
- Mar 2014
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of PF-04856884 in renal cell carcinoma (RCC) and solid tumor (6 arms), sponsored by Pfizer. Primary endpoints: Maximum Tolerated Dose and Progression-free Survival. Started Sep 2009; status: terminated.
02
Drugs
PF-04856884
03
Conditions
renal cell carcinoma (RCC)solid tumor
Beyond the preview
Go deeper on NCT00982657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00982657.